Core Viewpoint - JD Health's launch of a sleep center and internet sleep clinic aims to provide comprehensive, professional, and personalized sleep health solutions to millions suffering from sleep issues, integrating internet healthcare with health management [2][3]. Group 1: Market Demand and Context - Sleep issues are increasingly recognized as a significant health challenge, with nearly 25% of the population in China sleeping less than 6 hours and about 40% experiencing nighttime awakenings [2]. - The International Classification of Diseases (ICD-11) identifies over 90 types of sleep disorders, indicating a broad and urgent demand for diagnosis and treatment [2]. Group 2: Government Initiatives - The National Health Commission and the National Disease Control Bureau have mandated that by 2025, each city must have at least one hospital offering sleep clinic services, with similar requirements for districts in direct-controlled municipalities [3]. - The establishment of JD Health's sleep center aligns with national policies aimed at enhancing sleep disorder services [3]. Group 3: Service Offerings - JD Health's sleep center will utilize a combination of professional assessments and collaboration with top-tier hospital psychiatrists to provide comprehensive evaluations of users' sleep and psychological stress [3]. - The center will also feature an AI psychological companion, "Chatting with Yu Universe," available 24/7 to help alleviate user stress and promote healthy sleep [3]. Group 4: Product Availability - Users will have the option to purchase various sleep-related products, including medications, breathing machines, and melatonin, facilitating a one-stop shopping experience [4]. - The recent launch of the innovative drug Dazhuike® (generic name: Levorotary) on JD Health's platform represents a new treatment option for insomnia patients by precisely regulating sleep-wake rhythms [4]. Group 5: Future Plans - JD Health plans to deepen collaborations with medical institutions and experts to continuously improve service models and enhance user experience in sleep health services [4].

Core Insights - The launch of the new insomnia drug, Lemborexant (brand name: Dazai Ke), on e-commerce platforms in early August saw over 8,000 boxes sold on the first day, surprising the company [1] - Lemborexant is the first dual orexin receptor antagonist approved in China, marking a significant innovation in the insomnia treatment market after a decade without new drugs [1][2] - The drug has achieved a global sales forecast of $370 million in 2024, leading its category [1] - The drug's success in China was unexpected, as the company initially focused on the hospital market, but demand from e-commerce channels proved strong [1] Market Potential - There are hundreds of millions of people in China suffering from sleep disorders, indicating a vast potential market for insomnia treatments [2] - Lemborexant is not classified as a controlled substance, allowing easier access for patients compared to traditional sedative medications [2] Patient Experience - A patient named Li Wei, who has struggled with insomnia for years, reported positive experiences with Lemborexant, noting improved sleep quality without significant side effects [9] - However, not all patients have had the same success, with some experiencing difficulties in adjusting to the new medication [9] Treatment Guidelines - The treatment of insomnia requires a tailored approach, considering various underlying conditions and the need for proper medication management [10] - The company emphasizes the importance of rational drug use and gradual transitions from traditional medications to Lemborexant to avoid withdrawal symptoms [10][12] Healthcare System Challenges - There is a lack of specialized clinics for sleep disorders in China, making it difficult for patients to receive appropriate care [14] - The government is promoting the establishment of sleep clinics, with a goal for widespread availability by 2027, but challenges remain in integrating multidisciplinary approaches [14] Future Directions - The company plans to focus on sleep health management, aiming to expand market access for Lemborexant and develop new drugs targeting other sleep-related issues [15] - Collaboration with healthcare providers and institutions is encouraged to enhance clinical experience and public awareness regarding sleep health [15]

Core Insights - Eisai (China) Pharmaceutical Co., Ltd. has announced that its innovative drug, Lemborexant, has arrived in China and completed the drug inspection process, now being distributed to major hospitals and designated pharmacies nationwide, providing a new treatment option for insomnia patients [1][2] - Lemborexant can also be prescribed through the JD Health online platform, addressing the medication needs of insomnia sufferers [1] - The drug works by competitively binding to two orexin receptor subtypes (OX1R and OX2R), precisely regulating the orexin system to induce sleep without suppressing REM sleep, thus improving overall sleep structure [1][2] Product Approval and Market Position - Lemborexant was approved for sale in the United States in 2019 and has since received approval in over 20 countries and regions, including Japan, Canada, Australia, Hong Kong, and Macau [2] - In the U.S., it is indicated for adults with difficulties in falling asleep or maintaining sleep, while in Japan, it is a recommended treatment for insomnia as per the Japanese Consensus on Insomnia Disorder Treatment [2] - The drug received approval from the National Medical Products Administration (NMPA) in China in May 2025 for treating adult insomnia characterized by difficulty in falling asleep and/or maintaining sleep, and is included in the "Guidelines for the Diagnosis and Treatment of Adult Insomnia in China" [2] Strategic Focus - Eisai China positions the neuroscience field, including insomnia, as a key therapeutic area, aiming to provide innovative treatment options and management tools for insomnia patients [2] - The launch of Lemborexant is expected to reshape natural sleep rhythms and redefine sleep health management standards, contributing to the "Healthy China 2030" chronic disease prevention goals [2]